Microglia mediate chronic neuroinflammation following central nervous system (CNS) disease or injury, and in doing so, damage the local brain environment by impairing recovery and contributing to disease processes. Microglia are critically dependent on signaling through the colonystimulating factor 1 receptor (CSF1R) and can be eliminated via administration of CSF1R inhibitors.
. In humans, chronic neuroinflammation has been observed up to 17 years after traumatic brain injury (Ramlackhansingh et al., 2011) , and for decades after repetitive head injuries in American football athletes, correlating with dementia and chronic traumatic encephalopathy (Cherry et al., 2016) . Consequently, finding ways to manipulate and resolve microglial responses is a high priority.
We have determined that microglia in both the healthy (Dagher et al., 2015; Elmore, Lee, West, & Green, 2014) and injured brain (Rice et al., 2015; Spangenberg et al., 2016) are dependent upon signaling through the colony-stimulating factor 1 receptor (CSF1R) for their survival. Small-molecule inhibitors of the CSF1R that cross the blood brain barrier (BBB) rapidly eliminate microglia within days (Acharya et al., 2016; Elmore et al., 2014) . Microglia remain eliminated for the duration of treatment, be it days, weeks, or months (Elmore et al., 2014) . As chronic microglial responses are negatively implicated in neurodegenerative diseases and severe brain injuries, inhibition of the CSF1R may offer therapeutic promise (Rice et al., 2015; Spangenberg et al., 2016) .
However, because microglia are the primary immune cell of the CNS, it is unlikely that indefinite elimination of microglia from humans will be clinically feasible.
Crucially, we find that withdrawal of CSF1R inhibitors from microglia-depleted mice results in the rapid repopulation of the entire CNS with new cells within 14 days. Repopulation occurs both from the proliferation of surviving microglia and from progenitors that differentiate into microglia (Bruttger et al., 2015; Elmore et al., 2014) . Here, we set out to determine if we could eliminate and then fully repopulate microglia following extensive neuronal injury, and if such a strategy could represent a translatable opportunity to resolve chronic neuroinflammation and promote brain recovery.
| MATERIALS A ND METHODS

| Compounds
PLX5622 was provided by Plexxikon (Berkeley, CA) and formulated in standard chow by Research Diets at 1200 ppm. Doxycycline was provided in standard chow by Research Diets at 2000 mg/kg, or by researchers in deionized drinking water at 2 mg/ml (Sigma-Aldrich, St. Louis, MO) with 5% sucrose.
| Animal treatments
All rodent experiments were performed in accordance with animal protocols approved by the Institutional Animal Care and Use Committee at the University of California, Irvine. The CaM/Tet-diphtheria toxin A (DT A ) mouse model of inducible neuronal loss was employed for functional studies, and has been previously described (Yamasaki et al., 2007) , and was crossed with the Thy1-GFP-M mouse to enable visualization of neuronal structures (Feng et al., 2000) , as previously shown (Castello et al., 2014; Rice et al., 2015) . About 5-8 month-old male and female mice were maintained since birth on doxycycline chow (n 5 5-8 M/group; 4-7 F/group). Upon induction of the 30-day lesion period, doxycycline chow was replaced with standard chow. To cease expression of DT A , doxycycline was provided in drinking water, and after seven days, control or PLX5622 chow was provided for 14 days. Finally, PLX5622 treatment was withdrawn for 21 days, allowing microglia to fully repopulate. Behavioral tasks were performed during the final week of the study. At the conclusion of experiments, mice were sacrificed via lethal IP injection of Euthasol (Virbac AH, Fort Worth, TX) and perfused transcardially with 1X phosphate-buffered saline (PBS). Brains were extracted and dissected down the midline, with one half flash-frozen on dry ice for subsequent RNA and protein analyses, and the other half drop-fixed in 4% paraformaldehyde (PFA) in 1X PBS. Fixed brains were cryopreserved in a 30% sucrose solution, frozen, and sectioned at 40 lm on a Leica SM2000 R sliding microtome for subsequent immunohistochemical analyses.
| Confocal microscopy
Fluorescent immunolabeling followed a standard indirect technique (primary antibody followed by fluorescent secondary antibody), as previously described (Elmore et al., 2014) . Primary antibodies used include NeuN (1:1000; Abcam, Cambridge, MA), IBA1 (1:1000; Wako, Richmond, VA), GFAP (1:10,000; Abcam), S100b (1:1000, Abcam), CD45 (1:1000, AbD Serotec, Raleigh, NC) CD68 (1:2000, AbD Serotec), synaptophysin (1:500; Sigma Aldrich), and PSD95 (1:1000; Cell Signaling, Danvers, MA).
Numbers, size, and signal intensity of microglia, astrocytes, PSD95 puncta, and synaptophysin puncta were determined using the spots module in Bitplane Imaris 7.5 software. Synaptic puncta quantifications were obtained from high-resolution z-stack images, from equivocal brain regions.
| Behavioral testing
Mouse behavior was evaluated on elevated plus maze, accelerating rotarod (Elmore et al., 2014) , and Morris water maze (Baglietto-Vargas, Medeiros, Martinez-Coria, LaFerla, & Green, 2013) , in the order as presented, and as previously described.
| RNA extraction and analysis
RNA was extracted and purified from microdissected hippocampi of frozen half brains using Qiagen RNEasy Mini Kit (Hilden, Germany).
Total RNA was diluted to 20 ng/ll with nuclease-free water and protocols were carried out per manufacturer instructions. 182 inflammation-, Alzheimer's disease-(AD), plasticity-, and aging-related genes were selected for analysis and probes were designed and synthesized by NanoString nCounter TM technologies (Nanostring, Seattle, WA) against mouse genes, according to the manufacturer's instructions. Foldchange and calculated p-values were imported into Ingenuity Pathway
Analyses software suite (Qiagen), and predicted canonical pathways and upstream regulators identified, and z-scores calculated representing extent of predicted activation or inhibition.
| Dendritic spine analyses
Dendritic spine analysis was performed as previously described (Rice et al., 2015) .
| Statistics
One-way ANOVA with Bonferroni's multiple comparisons test was employed using GraphPad Prism (La Jolla, CA) to determine differences with PLX5622 treatment and repopulation timelines (Figure 1 ). Two- We first wanted to establish an appropriate treatment paradigm for microglial elimination and repopulation with the selective CSF1R antagonist PLX5622 (Acharya et al., 2016; Dagher et al., 2015; Klein et al., 2015; Schreiner et al., 2015; Valdearcos et al., 2014) , a more brainpenetrant and specific sister molecule of the clinically utilized PLX3397 (Tap et al., 2015) . We treated wild-type mice with either control chow or chow with 1200 ppm PLX5622 for seven days. In a subset of microglia-depleted mice, we then withdrew treatment for either three, seven, or 21 days to allow microglia to repopulate (Figure 1a , b; n 5 4 males per group). In accordance with our prior data, seven days of treatment eliminated 90% of microglia throughout the brain (Dagher et al., 2015) . Repopulating cells appeared three days following drug withdrawal and displayed enlarged cell bodies and a lack of ramification, consistent with our prior findings (Elmore et al., 2014) . By seven days of repopulation, microglia overshot in number to 160% of that in control mice, with their morphologies intermediate between that of cells seen at three days' repopulation, and normal ramified microglia (Figure 1b, c) . By 21 days of microglial repopulation, no significant differences existed in number or morphology of microglia between repopulated and control mice. As we previously showed (Elmore et al., 2014) , repopulating microglia are highly reactive for the lectin IB4 when they first appear, but are no longer reactive by 21 days (Figure 1b ).
Thus, seven days of PLX5622 treatment is sufficient to deplete the vast majority of microglia from the brain, while 21 days of repopulation allows microglia to return to normal numbers and morphology.
| Microglial elimination and repopulation following neuronal lesion
To make our studies relevant to both injury and disease, we utilized a tetracycline-off inducible transgenic CaM/Tet-DT A mouse, in which DT A chain is expressed in forebrain excitatory neurons upon withdrawal of doxycycline from the diet, leading to cellular death (Yamasaki et al., 2007) . The hippocampal region, specifically the CA1 subfield, exhibits the strongest lesion in these mice, followed by the cortex. This neuronal loss elicits a strong and prolonged neuroinflammatory response that lasts for months after the neuronal lesion has ended (Rice et al., 2015) . We further crossed CaM/Tet-DT A mice to the Thy1-GFP-M mouse line, yielding CaM/Tet-GFP mice, in which neuronal morphologies can be readily visualized (Castello et al., 2014; Feng et al., 2000) .
We induced a 30-day neuronal lesion in adult CaM/Tet-GFP mice (control mice do not harbor the CaM transgene, and therefore do not lesion upon doxycycline withdrawal), leading to the loss of 80% of CA1
neurons (Yamasaki et al., 2007) . We then re-administered doxycycline to stop further neuronal loss. After waiting seven days for expression of DT A to fully cease, we treated mice for 14 days with control chow or chow formulated with 1200 ppm PLX5622 to eliminate microglia.
PLX5622 at this dose eliminates 90% of all microglia within seven days ( Figure 1 ; [Acharya et al., 2016; Dagher et al., 2015; Schreiner et al., 2015; Valdearcos et al., 2014] ). Importantly, chronically activated microglia induced by this neuronal lesion model are eliminated with CSF1R inhibitors to the same extent as in control mice (Rice et al., 2015) . Once the microglia were eliminated (Figure 2d ), we withdrew PLX5622 treatment to stimulate microglial repopulation throughout the CNS and waited 21 days. This experimental paradigm effectively yields four experimental groups of mice, as seen in Figure 2a ,b:
(1) nonlesioned mice with resident microglia (Control; n 5 5M, 4F);
(2) nonlesioned mice with repopulated microglia (Repopulation; showed that lesioning dramatically increases the number of microglia within the brain, even 10 weeks after lesion initiation (Figure 2c , e).
Microglial repopulation in the nonlesioned mice resulted in microglial numbers precisely that of control levels, while microglial repopulation in the lesioned mice resulted in elevated microglial numbers to the same extent seen with only lesion.
| Repopulating microglia appear morphologically naïve
While we did not find a significant difference in the number of microglia between the Lesion and Lesion 1 Repopulation groups of mice, an obvious difference existed in the morphology of repopulated microglia following lesioning. Indicative of a reactive state, microglia in Lesion mice displayed highly swollen cell bodies, particularly in the dentate gyrus and in the cortex, stained more intensely for IBA1, and possessed short stubby processes. However, microglia in the Lesion 1 Repopulation mice resembled normal ramified microglia, with smaller somas and long, fine processes (Figure 3a, b) . Thus, these findings indicate that microglial 
| Microglial elimination and repopulation increases total spine number
In the design of our experiment, we included the Thy1-GFP-M transgene to explore how microglial repopulation affects the synaptic landscape (Figure 5a, b) . Quantification of dendritic spine densities on CA1 nonprimary apical neurons revealed a robust increase with just two weeks of microglial elimination; these increases were further sustained Representative flattened z-stack images of PSD95 and synaptophysin immunoreactivity in the CA1 region display alterations in puncta area and size. Quantification of PSD95 puncta number (e) and volume (f) shows that microglial repopulation increases puncta numbers, while lesion increases puncta volume. Quantification of synaptophysin puncta number (g) and volume (h) shows that microglial repopulation increases puncta numbers, with no significant effects on puncta volume. Error bars indicate SEM, (n 5 7-10/group). Symbols denote significant differences between groups (p < 0. Figure   5c ; n 5 5-7). These increases were seen in mushroom and thin spines, with no effect on stubby spines. Lesioning had no effect on total spine density, but significantly reduced stubby spines; this phenomenon was seen regardless of microglial repopulation status. However, no significant differences were seen between Lesion and Lesion 1 Repopulation groups. Previously, we found that both lesioning and microglial elimination had dramatic effects on the number and properties of synaptophysin and PSD95 puncta, markers of pre-and postsynaptic areas, respectively (Rice et al., 2015) . Quantification of these markers revealed that microglial repopulation significantly increases the number of PSD95 and synaptophysin puncta in both Control and Lesion mice (Figure 5d , e, and g). Lesion alone dramatically increased PSD95 puncta size (Figure 5f ).
| Microglial repopulation rescues behavioral deficits induced by neuronal lesion
We tested motor and cognitive abilities prior to sacrificing the mice to determine how microglial repopulation affects functional recovery. Finally, we assessed motor function via swim speed during the Morris water maze and time to fall during accelerating rotarod. Although lesioning had a significant main effect on accelerating rotarod performance (p < 0.05), mice in all four groups exhibited similar swim speeds in the water maze (Figures 6b, d ).
| Microglial repopulation dampens lesion-induced inflammation
We sought to explore the effects of lesioning and microglial repopulation by measuring levels of mRNA in dissected hippocampal tissue via Nanostring technology. To that end we created a custom gene set encompassing 101 genes related to neurodegeneration, synaptic plasticity, and learning and memory, and a further 81 genes related to neuroinflammation. Of interest, several Alzheimer's disease (AD)-related genes were upregulated with lesion, including ABCA1, APOE, APP, BIN1, CAPN1, LRP1, MAPT, and PSEN2. These genes encompass pathological proteins implicated in the disease (APP, PSEN2, and MAPT), as well as genetic risk factors (APOE, BIN1, and LRP1; also TREM2 in the inflammatory panel [ Figure 7 ]), and demonstrate how neuronal injury alone upregulates genes implicated in the development of AD (Figure 7a ). Of these AD genes, APOE and CTSB, CTSC, and CTSD (Cathepsins B, C, and D) were all significantly increased in Lesion compared with Control, but attenuated in Lesion 1 Repopulation compared with Lesion (Figure 7a) . Of the other genes, ANXA5 (Annexin A5), CDK2 (Cyclin-dependent kinase 2), and CDKN1C (Cyclin-dependent kinase inhibitor 1C) were significantly lowered in Lesion 1 Repopulation, compared with Lesion alone (Figure 7b ). Five neurotransmission-related genes decreased with lesioning, and four increased. Of these, only two lesion-associated increases are rescued by microglial repopulation-FGF2 (fibroblast growth factor 2), which is upregulated by astrocytes with brain lesion (Clarke, Berry, Smith, Kent, & Logan, 2001) , and GFRA1, which is a receptor for GDNF (Cik et al., 2000) . Pathway analyses of gene expression changes highlighted several predicted upstream regulators, with APP being the most significant, followed by inflammatory molecules, such as IFNG and TNF (Figure 7c ). The downstream gene activation states from APP in control and lesioned mice were plotted, and revealed that lesioning upregulated inflammatory signals, but downregulated molecules associated with plasticity and memory (Figure 7d ). Thus, neuronal loss itself recapitulates many of the pathway changes seen in the AD brain (Matarin et al., 2015) .
Having shown that microglial repopulation following extensive neuronal injury has dramatic effects on the localization and morphology of reactive microglia, we characterized neuroinflammatory signaling in the brain by directly analyzing mRNA levels for 81 inflammatory-related genes. Forty-six of the surveyed inflammatory-associated genes were upregulated in mice that were lesioned. This finding demonstrates a robust and chronic neuroinflammatory response to the lesioning paradigm, despite 10 weeks having passed since the lesion began. Of the 46 genes that were increased with lesion, 28 were significantly reduced with microglial repopulation (Figure 8a ). These genes encode proteins 
| DISCUSSION
Microglia become primed with age, disease, and injury, wherein they fail to resolve insults and instead remain chronically activated (Holtman et al., 2015; Perry & Holmes, 2014; Wes, Holtman, Boddeke, Moller, & Eggen, 2016) . Such chronic inflammation is a key component of most CNS insults, and harms the local brain environment through the production of inflammatory substances such as reactive oxygen species and cytokines (Liu, Amaral, Brosnan, & Lee, 1998; Renno, Krakowski, Piccirillo, Lin, & Owens, 1995) . Additionally, chronically activated microglia can physically interact with other cell types such as neurons to facilitate synaptic stripping (Trapp et al., 2007; Wake, Moorhouse, Jinno, Kohsaka, & Nabekura, 2009 ). Thus, identifying effective ways to control and resolve chronic neuroinflammation is a pressing issue with relevance to the majority of CNS disorders and injuries.
Microglia are critically dependent upon CSF1R signaling; CSF1R knockout mice do not develop microglia (Erblich, Zhu, Etgen, Dobrenis, & Pollard, 2011; Ginhoux et al., 2010) , while pharmacologic inhibition of the CSF1R rapidly eliminates most microglia from the brain (Elmore et al., 2014) , including those in an activated state (Rice et al., 2015) , without detrimental effects to the animal. Microglia remain eliminated for the duration of treatment, but withdrawal of CSF1R inhibition stimulates robust and rapid repopulation of the entire CNS with new cells that become microglia Elmore et al., 2014) , effectively replacing the entire microglial compartment. As CSF1R inhibitors are currently used in the clinic, and more are being developed (Tap et al., 2015) , these molecules offer a powerful tool against neuroinflammation. As chronic microglial elimination after injury or during disease might not be clinically feasible,
we have explored the potential of short-term microglial depletion, followed by repopulation of the microglial compartment, to assess the effects on neuroinflammation, neuronal structures, and functional recovery.
Critically, our data reveal that we can renew the microglial compartment in the face of massive inflammation, and that doing so results in robustly positive effects. Firstly, repopulation resolves many aspects of chronic neuroinflammation, including microglial morphology and expression of reactive markers, as well as inflammatory transcripts. Secondly, elimination and subsequent repopulation appears to increase synaptic surrogates, such as dendritic spines and synaptophysin and PSD95 puncta numbers. Remarkably, just two weeks of microglial elimination is sufficient to dramatically increase spine densities, revealing a critical homeostatic role for microglia in regulating neuronal structures. Finally, and most importantly, microglial repopulation results in an almost complete reversal of behavioral impairment, despite the continued deficit in forebrain neurons, suggesting that repopulation promotes an environment for recovery.
Additionally, these data provide insight as to the nature of microglia and sustained inflammatory responses. That repopulating microglia appear to be less reactive than the microglia they replaced suggests that unresolved chronic inflammation is inherent within the cells themselves, rather than being fully dictated by the environment. This may help to explain why microglia fail to return to a quiescent state following damage, such as a traumatic brain injury (Cherry et al., 2016; Ramlackhansingh et al., 2011 ).
In conclusion, we present a novel approach to the resolution of chronic neuroinflammatory events and the promotion of brain repair.
We propose that CSF1R-dependent elimination of chronically reactive microglia followed by microglial repopulation can potentially offer a lasting solution to chronic inflammation and improve functional outcomes in individuals who have suffered severe brain insults. 
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